A-397 - Prognostic value of tumor microenvironment molecules in the response to immunotherapy in advanced melanoma

Autor: Parra-Navarro, L., Calon, A., Iglesias-Coma, M., Andrades-López, E., Sallent-Aragay, A., Solé-Blanch, C., Vidal-Barrull, J., España-Fernández, S., Martínez-Cardús, A., Pujol, R.M., Segura, S.

Publikováno v: In EJC Skin Cancer 2024 2 Supplement 1

Dual inhibition of MEK and PI3Kβ/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.

Autor: Ruiz de Porras V; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain.; GRET and Toxicology Unit, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain., Bernat-Peguera A; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain., Alcon C; Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., Laguia F; IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain., Fernández-Saorin M; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain., Jiménez N; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain., Senan-Salinas A; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain., Solé-Blanch C; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain., Feu A; Department of Pathology, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain., Marín-Aguilera M; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain., Pardo JC; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Barcelona, Spain., Ochoa-de-Olza M; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Barcelona, Spain., Montero J; Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain., Mellado B; Translational Genomics and Targeted Therapeutics in Solid Tumors Lab, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.; Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain., Font A; CARE Program, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Barcelona, Spain.; Medical Oncology Department, Catalan Institute of Oncology, Badalona, Barcelona, Spain.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2024 Jan 22; Vol. 15, pp. 1331648. Date of Electronic Publication: 2024 Jan 22 (Print Publication: 2024).

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.

Autor: Ruiz de Porras V; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain., Wang XC; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain., Palomero L; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain., Marin-Aguilera M; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Solé-Blanch C; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain., Indacochea A; Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain., Jimenez N; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Bystrup S; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Program Against Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Gran Via de L'Hospitalet, Barcelona, Spain., Bakht M; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA., Conteduca V; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA; Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy., Piulats JM; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain., Buisan O; Department of Urology, Hospital Germans Trias I Pujol, Badalona, Spain., Suarez JF; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain; Department of Urology, Bellvitge University Hospital, Hospitalet de Llobregat, Barcelona, Spain., Pardo JC; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., Castro E; Genitourinary Cancer Translational Research Group, The Institute of Biomedical Research in Málaga, Málaga, Spain; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain., Olmos D; Genitourinary Cancer Translational Research Group, The Institute of Biomedical Research in Málaga, Málaga, Spain; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain., Beltran H; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA., Mellado B; Translational Genomics and Targeted Therapeutics in Solid Tumors Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clínic, Barcelona, Spain., Martinez-Balibrea E; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain; Program Against Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Gran Via de L'Hospitalet, Barcelona, Spain., Font A; Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, Spain; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain. Electronic address: afont@iconcologia.net., Aytes A; Program of Molecular Mechanisms and Experimental Therapeutics in Oncology, Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet de Llobregat, Gran Via de L'Hospitalet, Barcelona, Spain; Program Against Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Gran Via de L'Hospitalet, Barcelona, Spain. Electronic address: aaytes@idibell.cat.

Publikováno v: European urology [Eur Urol] 2021 Jun; Vol. 79 (6), pp. 722-733. Date of Electronic Publication: 2020 Nov 03.

Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.

Autor: Winter, Ruth Christine¹ (AUTHOR) ruth.winter@dkfz-heidelberg.de, Amghar, Mariam¹ (AUTHOR) mariam.amghar@dkfz-heidelberg.de, Wacker, Anja S.² (AUTHOR) anw4010@med.cornell.edu, Bakos, Gábor¹ (AUTHOR) gabor.bakos01@gmail.com, Taş, Harun¹ (AUTHOR) harun.tas@dkfz-heidelberg.de, Roscher, Mareike³ (AUTHOR) mareike.roscher@dkfz-heidelberg.de, Kelly, James M.² (AUTHOR) jak2046@med.cornell.edu, Benešová-Schäfer, Martina¹ (AUTHOR) m.benesova@dkfz-heidelberg.de

Publikováno v: Pharmaceuticals (14248247). Aug2024, Vol. 17 Issue 8, p1031. 47p.

Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.

Autor: Quagliariello, V., Passariello, M., Bisceglia, I., Paccone, A., Inno, A., Maurea, C., Lembo, R. Rapuano, Manna, L., Iovine, M., Canale, M. L., Scherillo, M., Ascierto, P. A., Gabrielli, D., De Lorenzo, C., Maurea, N.

Publikováno v: Frontiers in Cardiovascular Medicine; 2024, p1-18, 18p